Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial
Author
White, M.
Gianni, L.
Lang, I.
Toi, M.
Taran, T.
Jerusalem, G.
Andre, F.
Chen, D.
Robinson, D.
Ozguroglu, M.
Metadata
Show full item recordCollections
- Makale [92796]